Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 1/20 | 0.64 |
| ▸ | PPARG | P37231 | 2/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.62 |
| ▸ | REN | P00797 | 3/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.56 |
| ▸ | CTSS | P25774 | 2/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.56 |
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 1/20 | 0.55 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.54 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.54 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.54 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
| ▸ | YAP1 | P46937 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL793015 | 0.91 | BCL2 (0.62) | BCL2PPARGPTPN1RENHDAC8 | |
| SCHEMBL193473 | 0.91 | PTPN1 (0.73) | BCL2PPARGPTPN1HDAC8ITGB3 | |
| SCHEMBL2891538 | 0.91 | PTPN1 (0.73) | BCL2PPARGPTPN1HDAC8ITGB3 | |
| SCHEMBL193474 | 0.91 | PTPN1 (0.73) | BCL2PPARGPTPN1HDAC8ITGB3 | |
| SCHEMBL4420859 | 0.89 | REN (0.67) | PPARGRENCTSSCTSLCTSB | |
| SCHEMBL2173588 | 0.89 | REN (0.67) | PPARGRENCTSSCTSLCTSB | |
| SCHEMBL7618822 | 0.89 | REN (0.67) | PPARGRENCTSSCTSLCTSB | |
| SCHEMBL9752771 | 0.89 | BCL2 (0.64) | BCL2PPARGPTPN1RENHDAC8 | |
| SCHEMBL3350988 | 0.89 | BCL2 (0.64) | BCL2PPARGPTPN1RENHDAC8 | |
| SCHEMBL9752770 | 0.89 | BCL2 (0.64) | BCL2PPARGPTPN1RENHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | BCL2 3606/4885PPARG 736/4885PTPN1 319/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | BCL2 3606/4885PPARG 736/4885PTPN1 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.